Neuroendocrine Carcinoma Clinical Trial
Official title:
Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)
A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA. NP-101 (TQ Formula) (TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and has anti-oxidant, anti-angiogenic effects.
The purpose of this study is to find out if NP-101 (TQ Formula) given with the immunotherapy drugs called nivolumab and ipilimumab helps with neuroendocrine carcinoma who have progressed on at least one first line standard therapy. NP-101 (TQ Formula) black seed oil tablet is an investigational (experimental) drug that may enhance the effect that immunotherapy drugs such as nivolumab and ipilimumab have on neuroendocrine carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01642251 -
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04069299 -
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
|
||
| Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
| Recruiting |
NCT04325425 -
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
|
Phase 2 | |
| Completed |
NCT03834701 -
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
|
N/A | |
| Recruiting |
NCT03279614 -
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05978284 -
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076786 -
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Completed |
NCT00388063 -
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT03901378 -
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02970786 -
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
|
Phase 1 | |
| Completed |
NCT00663429 -
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
| Completed |
NCT03278405 -
Avelumab in G3 NEC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03837977 -
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
| Active, not recruiting |
NCT02687958 -
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
|
Phase 2 | |
| Completed |
NCT01121939 -
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
|
Phase 2 | |
| Recruiting |
NCT03168607 -
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 | |
| Enrolling by invitation |
NCT05396118 -
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
|
Phase 2 |